ACSL3 and non-small cell lung carcinoma: Since fatty acid‐related ACSL3 determines poor clinical prognosis in NSCLC, we analyzed the effect of statins administration in an ACSL3 overexpressing scenario, which would correspond to 76.6% of the NSCLC patients.